

# Risk of non-AIDS-defining events amongst HIV-infected patients not yet on antiretroviral therapy

Ard van Sighem<sup>1</sup>; Anouk Kesselring<sup>1</sup>; Luuk Gras<sup>1</sup>; Jan Prins<sup>2</sup>; Elly Hassink<sup>3</sup>; Robert Kauffmann<sup>4</sup>, Clemens Richter<sup>5</sup>, Peter Reiss<sup>1,2</sup>, Frank de Wolf<sup>6</sup>

<sup>1</sup>Stichting HIV Monitoring, Amsterdam, NL; <sup>2</sup>Academic Medical Centre, Amsterdam, NL; <sup>3</sup>Soa Aids Nederland, Amsterdam, NL; <sup>4</sup>HAGA hospital, The Hague, NL; <sup>5</sup>Rijnstate Hospital, Arnhem, NL; <sup>6</sup>Imperical College School of Medicine, London, UK; on behalf of the ATHENA national observational HIV cohort

# **Background**

- •Certain non-AIDS-defining illnesses in HIV-infected patients on combination antiretroviral therapy (cART) have been associated with low CD4 cell counts and high HIV RNA levels.
- •We aimed to further investigate these associations in patients not yet on cART when potential antiretroviral drug-related toxicities are absent and there is more variation in RNA levels.

## **Methods**


#### Patient population

- •13,077 patients from the ATHENA national observational HIV cohort who were
  - diagnosed with HIV-1 ≥1998.
- not yet treated with cART.

#### **Analysis**

- •Poisson regression model for the association between time-updated CD4 counts and HIV RNA and a composite non-AIDS endpoint.
- Composite endpoint included:
- major cardiovascular disease: myocardial infarction, stroke, invasive coronary procedures.
- liver fibrosis/cirrhosis.
- non-AIDS malignancies.
- •Non-AIDS events were considered from the time of the first CD4 count onwards.
- •Patients were followed until start of treatment or last follow-up visit.

Figure 1: Incidence of non-AIDS-defining events across categories of latest CD4 count and HIV RNA in HIV-infected patients not yet on antiretroviral treatment. Error bars indicate 95% confidence intervals. PY: person-years.



### **Results**

- •18,641 person-years of follow-up.
- •208 (1.6%) patients with one or more non-AIDS events: 5 patients had ≥2 events:
  - 53 cardiovascular disease.
  - 79 liver fibrosis/cirrhosis.
  - 82 non-AIDS malignancies.

**Table 1**: Association between latest CD4 count and HIV RNA and the composite non-AIDS endpoint. Multivariate analyses were adjusted for demography, history of smoking, alcohol use, CDC stage, hepatitis B and C coinfection, diabetes, and hypertension. RR: relative risk; CI: confidence interval; ref: reference.

	Univariate		Multivariate	
	RR	95% CI	RR	95% CI
CD4 [cells/mm <sup>3</sup> ]				
<200	8.96	6.15-13.0	4.36	2.83-6.73
200-349	2.51	1.71-3.68	2.13	1.45-3.14
350-499	1.35	0.93-1.95	1.23	0.85-1.78
≥500	ref		ref	
HIV RNA [copies/ml]				
<20,000	0.48	0.34-0.68	1.13	0.77-1.66
20,000-	0.75	0.53-1.06	1.34	0.93-1.93
99,999				
≥100,000	ref		ref	

## **Conclusions**

- •In persons not yet receiving cART, a more severe degree of immunodeficiency rather than HIV RNA appears to be associated with an overall risk of our composite non-AIDS event endpoint.
- •Larger studies will be needed to address these associations for each individual non-AIDS disease event.

## Contact

Ard van Sighem Stichting HIV Monitoring E: a.i.vansighem@amc.uva.nl T: +31205666781 www.hiv-monitoring.nl